Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
long-acting beta2-agonists + inhaled corticosteroids
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
A **combination inhaler** containing a **long-acting beta2-agonist** (LABA) and an **inhaled corticosteroid** (ICS) is used primarily for the treatment of asthma and chronic obstructive pulmonary disease (COPD)[1][2][5]. LABAs act on airway smooth muscle to produce bronchodilation, improving airflow and reducing symptoms, while ICS suppress airway inflammation and decrease exacerbation frequency. The two classes address complementary aspects of airway pathology—bronchodilation and inflammation control—and have additive or synergistic effects when used together. Common commercial combinations include **fluticasone/salmeterol** (Advair/Seretide) and **budesonide/formoterol** (Symbicort)[1][2][3].
- Brand names
- AdvairSeretideVianiSymbicortVannair
- Other names
- LABA + ICSlong-acting beta2-agonist + inhaled corticosteroidinhaled corticosteroid + long-acting beta2-agonistICS/LABA combination inhaler
02
Targets
ADRB2 (β2)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on long-acting beta2-agonists + inhaled corticosteroids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on long-acting beta2-agonists + inhaled corticosteroids.